Z

Zhejiang Tianyu Pharmaceutical Co Ltd
SZSE:300702

Watchlist Manager
Zhejiang Tianyu Pharmaceutical Co Ltd
SZSE:300702
Watchlist
Price: 17.31 CNY 2.43%
Market Cap: 6B CNY
Have any thoughts about
Zhejiang Tianyu Pharmaceutical Co Ltd?
Write Note

Zhejiang Tianyu Pharmaceutical Co Ltd
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zhejiang Tianyu Pharmaceutical Co Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Z
Zhejiang Tianyu Pharmaceutical Co Ltd
SZSE:300702
Total Receivables
ÂĄ567.5m
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Receivables
ÂĄ3.3B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Receivables
ÂĄ1.1B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Receivables
ÂĄ7.5B
CAGR 3-Years
-7%
CAGR 5-Years
3%
CAGR 10-Years
10%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Receivables
ÂĄ13.2B
CAGR 3-Years
18%
CAGR 5-Years
13%
CAGR 10-Years
11%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Receivables
ÂĄ172.9m
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zhejiang Tianyu Pharmaceutical Co Ltd
Glance View

Market Cap
6B CNY
Industry
Pharmaceuticals

Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of chemical raw materials and intermediates. The company is headquartered in Taizhou, Zhejiang and currently employs 4,991 full-time employees. The company went IPO on 2017-09-19. The firm operates three segments. The Pharmaceutical Intermediates segment include hypertension drugs raw materials, anti-asthma drugs raw materials and anticoagulant drugs raw materials. The Active Pharmaceutical Ingredients (API) segment is engaged in production of high blood pressure drug intermediates, anti-asthma drug intermediates and antiviral drug intermediates. The firm also operates Other segment. The firm sells its products to both domestic and international markets, including Europe, the United States, Japan, South Korea and so on.

Intrinsic Value
20.86 CNY
Undervaluation 17%
Intrinsic Value
Price
Z

See Also

What is Zhejiang Tianyu Pharmaceutical Co Ltd's Total Receivables?
Total Receivables
567.5m CNY

Based on the financial report for Sep 30, 2024, Zhejiang Tianyu Pharmaceutical Co Ltd's Total Receivables amounts to 567.5m CNY.

What is Zhejiang Tianyu Pharmaceutical Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 5Y
7%

Over the last year, the Total Receivables growth was 10%. The average annual Total Receivables growth rates for Zhejiang Tianyu Pharmaceutical Co Ltd have been 6% over the past three years , 7% over the past five years .

Back to Top